Status:
UNKNOWN
Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation After Cataract Surgery
Lead Sponsor:
Evolutec Group
Conditions:
Ocular Inflammation
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of three concentrations of rEV131, a new investigational anti-inflammatory agent, compared to placebo (an inactive substance) and ...
Eligibility Criteria
Inclusion
- be male or female who has undergone unilateral cataract extraction by phacoemulsification (PHACO) method with implantation of a posterior chamber intraocular lens
Exclusion
- have unstable glaucoma
- have an active bacterial and/or viral infection
- use any ocular or systemic anti-inflammatory agents within 1 week prior to enrollment and for the duration of the study.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00353964
Last Update
July 28 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ORA Study Sites
North Andover, Massachusetts, United States, 01845